Last reviewed · How we verify

Daunorubicin or Idarubicin

Stichting Hemato-Oncologie voor Volwassenen Nederland · Phase 3 active Small molecule

Daunorubicin or Idarubicin is a Anthracycline topoisomerase II inhibitor Small molecule drug developed by Stichting Hemato-Oncologie voor Volwassenen Nederland. It is currently in Phase 3 development for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Chronic myeloid leukemia (CML) in blast crisis. Also known as: Part 1 Block 2 induction FLADx.

Daunorubicin and idarubicin are anthracycline chemotherapy agents that intercalate into DNA and inhibit topoisomerase II, leading to DNA damage and cancer cell death.

Daunorubicin and idarubicin are anthracycline chemotherapy agents that intercalate into DNA and inhibit topoisomerase II, leading to DNA damage and cancer cell death. Used for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Chronic myeloid leukemia (CML) in blast crisis.

At a glance

Generic nameDaunorubicin or Idarubicin
Also known asPart 1 Block 2 induction FLADx
SponsorStichting Hemato-Oncologie voor Volwassenen Nederland
Drug classAnthracycline topoisomerase II inhibitor
TargetTopoisomerase II, DNA
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

These drugs belong to the anthracycline class and work by inserting themselves between DNA base pairs (intercalation) and blocking topoisomerase II, an enzyme essential for DNA replication and transcription. This dual mechanism causes double-strand DNA breaks and apoptosis in rapidly dividing cancer cells. They are particularly effective against hematologic malignancies.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Daunorubicin or Idarubicin

What is Daunorubicin or Idarubicin?

Daunorubicin or Idarubicin is a Anthracycline topoisomerase II inhibitor drug developed by Stichting Hemato-Oncologie voor Volwassenen Nederland, indicated for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Chronic myeloid leukemia (CML) in blast crisis.

How does Daunorubicin or Idarubicin work?

Daunorubicin and idarubicin are anthracycline chemotherapy agents that intercalate into DNA and inhibit topoisomerase II, leading to DNA damage and cancer cell death.

What is Daunorubicin or Idarubicin used for?

Daunorubicin or Idarubicin is indicated for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Chronic myeloid leukemia (CML) in blast crisis.

Who makes Daunorubicin or Idarubicin?

Daunorubicin or Idarubicin is developed by Stichting Hemato-Oncologie voor Volwassenen Nederland (see full Stichting Hemato-Oncologie voor Volwassenen Nederland pipeline at /company/stichting-hemato-oncologie-voor-volwassenen-nederland).

Is Daunorubicin or Idarubicin also known as anything else?

Daunorubicin or Idarubicin is also known as Part 1 Block 2 induction FLADx.

What drug class is Daunorubicin or Idarubicin in?

Daunorubicin or Idarubicin belongs to the Anthracycline topoisomerase II inhibitor class. See all Anthracycline topoisomerase II inhibitor drugs at /class/anthracycline-topoisomerase-ii-inhibitor.

What development phase is Daunorubicin or Idarubicin in?

Daunorubicin or Idarubicin is in Phase 3.

What are the side effects of Daunorubicin or Idarubicin?

Common side effects of Daunorubicin or Idarubicin include Cardiotoxicity / cardiomyopathy, Myelosuppression (neutropenia, thrombocytopenia, anemia), Nausea and vomiting, Mucositis, Alopecia, Secondary malignancy.

What does Daunorubicin or Idarubicin target?

Daunorubicin or Idarubicin targets Topoisomerase II, DNA and is a Anthracycline topoisomerase II inhibitor.

Related